RxSight, Inc. (RXST) stock

RXSTNasdaqOphthalmic GoodsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3074% below fair value

$5.38+0.10 (+1.89%)

Close on Nov 12, 2026Market cap $223.77MP/E –Yield –

RxSight ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

RxSight's ebitda for the twelve months ending Jun 30, 2026 was -$51.58M. For fiscal 2025 it was -$44.93M. The highest annual figure on record is -$31.56M in fiscal 2020.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$44.93M	–
FY2024	Dec 31, 2024	-$33.28M	–
FY2023	Dec 31, 2023	-$46.01M	–
FY2022	Dec 31, 2022	-$59.43M	–
FY2021	Dec 31, 2021	-$48.81M	–
FY2020	Dec 31, 2020	-$31.56M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q2 FY2026	Jun 30, 2026	-$12.77M	–
Q1 FY2026	Mar 31, 2026	-$17.00M	–
Q4 FY2025	Dec 31, 2025	-$10.49M	–
Q3 FY2025	Sep 30, 2025	-$11.32M	–
Q2 FY2025	Jun 30, 2025	-$13.22M	–
Q1 FY2025	Mar 31, 2025	-$9.90M	–
Q4 FY2024	Dec 31, 2024	-$8.11M	–
Q3 FY2024	Sep 30, 2024	-$8.09M	–
Q2 FY2024	Jun 30, 2024	-$7.52M	–
Q1 FY2024	Mar 31, 2024	-$9.56M	–
Q4 FY2023	Dec 31, 2023	-$9.80M	–
Q3 FY2023	Sep 30, 2023	-$11.43M	–
Q2 FY2023	Jun 30, 2023	-$12.64M	–
Q1 FY2023	Mar 31, 2023	-$12.14M	–
Q4 FY2022	Dec 31, 2022	-$14.07M	–
Q3 FY2022	Sep 30, 2022	-$15.02M	–
Q2 FY2022	Jun 30, 2022	-$14.78M	–
Q1 FY2022	Mar 31, 2022	-$15.56M	–
Q4 FY2021	Dec 31, 2021	-$13.64M	–
Q3 FY2021	Sep 30, 2021	-$12.11M	–
Q2 FY2021	Jun 30, 2021	-$12.89M	–
Q1 FY2021	Mar 31, 2021	-$10.18M	–
Q4 FY2020	Dec 31, 2020	-$7.32M	–
Q3 FY2020	Sep 30, 2020	-$7.87M	–